SOHO 2023 | Value of MRD status one month after CAR-T therapy in patients with multiple myeloma
CAR-T cell therapies have transformed the treatment landscape of multiple myeloma. In this video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into the prognostic value of bone marrow measurable residual disease (MRD) status one month after CAR-T cell therapy in patients with multiple myeloma. Dr Lin explains that early MRD negativity is associated with prolonged progression-free survival (PFS), with patients thought to have a higher risk of disease progression if they do not achieve this. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bluebird Bio: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Gamida Cell: Consultancy; Takeda: Research Funding; Vineti: Consultancy; Sorrento: Consultancy; Merck: Research Funding.
